– Industry veteran, Christine D. Baker, joins Board of
Directors
– Douglas A. Michels appointed Chairman of the Board
TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an
emerging biotechnology company developing cancer metabolism-based
therapies (CMBTs™), today announced changes to its Board of
Directors.
Christine D. Baker Named to Board of Directors
The Company is pleased to announce that Christine D. Baker has
been appointed to TYME’s Board of Directors. Ms. Baker brings over
30 years of experience in the biotech/pharmaceutical industry, with
expertise in business development, commercialization, and drug
development strategies. She is currently the Chief Business Officer
of Hookipa Pharma, a public, clinical-stage biotechnology company,
where she leads Business Development, Alliance Management,
Commercial Strategy, Intellectual Property, and Communications.
Prior to this, Ms. Baker provided commercial development consulting
services to biotech companies as the principal of CD Baker
Consulting and was also the Chief Business Officer of EpicentRX, a
privately held clinical-stage biotechnology company. She also held
several management positions at Novartis Pharmaceuticals
Corporation, including Vice President and Executive Director,
Oncology Early Commercial Strategy. Ms. Baker began her career at
Schering-Plough, where she advanced through a variety of roles in
R&D, Marketing and Sales, Business Development, and General
Management. Ms. Baker holds a degree in Chemistry from Dartmouth
College and an MBA from Rutgers University.
“We are delighted to welcome Christine to our Board of
Directors. In addition to Christine’s commercial and business
development experience, her considerable industry expertise will be
instrumental in helping to guide TYME in our quest to eradicate
advanced cancers,” said Douglas A. Michels, Chairman of the Board
of TYME.
“I am impressed with TYME’s pipeline and novel approach to
finding solutions that make a difference in people’s lives. As a
member of the Board of Directors, I look forward to sharing my
experience and perspectives with management as we seek to develop
our pipeline,” said Ms. Baker.
The Company is also announcing that co-founder Steven Hoffman
has stepped down from his role as Chief Scientific Officer but will
continue to support TYME’s efforts as a member of the Board of
Directors.
Douglas A. Michels Named Chairman of the Board
Mr. Michels, who currently serves on TYME’s Board of Directors
as Lead Independent Director, will assume the role of Chairman of
the Board.
Mr. Michels, who has served on TYME’s Board of Directors since
October 2018, has over 39 years of experience in the healthcare
industry. Most recently, he served as President and Chief Executive
Officer of OraSure Technologies, Inc. Prior to OraSure, Mr. Michels
spent 19 years with Johnson & Johnson in a range of executive
positions, including as President of Ortho Clinical Diagnostics
International and President of Johnson & Johnson Healthcare
Systems. He currently serves on the Board of Directors of West
Pharmaceutical Services, Inc. (NYSE:WST). In February 2010, Mr.
Michels was appointed to the Presidential Advisory Council on
HIV/AIDS by President Barack Obama.
“Mr. Michels has brought valuable insights to TYME during the
past four years. His skillset and experience make him well suited
to serve as our Chairman at this time,” stated Richie Cunningham,
Chief Executive Officer of TYME.
About TYME Technologies, Inc.
TYME is an emerging biotechnology company developing cancer
metabolism-based therapies (CMBTs™) that are intended to be
effective across a broad range of solid tumors and hematologic
cancers, while also maintaining patients’ quality of life through
relatively low toxicity profiles. Unlike targeted therapies that
attempt to regulate specific mutations within cancer, the Company’s
therapeutic approach is designed to take advantage of a cancer
cell’s innate metabolic weaknesses to cause cancer cell death.
The Company is currently focused on developing its novel
compound, SM-88, its preclinical pipeline of novel CMBTTM programs,
as well as TYME-19 as a potential therapeutic for SARS CoV-2
diseases. The Company believes that early clinical results
demonstrated by SM-88 in multiple advanced cancers, including
prostate, sarcomas and breast, reinforce the potential of its
emerging CMBT™ pipeline.
For more information about the Company, visit www.tymeinc.com
and connect on Facebook, LinkedIn, and Twitter.
About SM-88
SM-88 is an oral investigational modified proprietary tyrosine
derivative that is believed to interrupt the metabolic processes of
cancer cells by breaking down the cells’ key defenses and leading
to cell death through oxidative stress and exposure to the body’s
natural immune system. Clinical trial data have shown that SM-88
has demonstrated encouraging tumor responses across 15 different
cancers, including lung, breast, prostate and sarcoma cancers with
minimal serious grade 3 or higher adverse events. SM-88 is being
evaluated in a Phase II study evaluating SM-88 in breast cancer
(HR+/HER2-), as well as continuing enrollment of a Phase II study
in high-risk metastatic sarcomas. SM-88 is an investigational
therapy that is not approved for any indication in any disease.
Learn more.
Forward-Looking Statements
In addition to historical information, this press release
contains forward-looking statements under the Private Securities
Litigation Reform Act that involve substantial risks and
uncertainties. Such forward-looking statements within this press
release include, without limitation, statements regarding our drug
candidates and technologies (including SM-88 and TYME- 18) and
their clinical potential and non-toxic safety profiles, our drug
development plans and strategies, ongoing and planned preclinical
or clinical trials, preliminary data results and the therapeutic
design and mechanisms of our drug candidates. The words “believes,”
“expects,” “hopes,” “may,” “will,” “plan,” “intends,” “estimates,”
“could,” “should,” “would,” “continue,” “seeks,” “anticipates,” and
similar expressions (including their use in the negative) are
intended to identify forward-looking statements. Forward-looking
statements can also be identified by discussions of future matters
such as: the effect of the COVID-19 pandemic and the associated
impact on the national and global economy as well as impacts on the
Company's ongoing clinical trials and ability to analyze data from
those trials; the cost of development and potential
commercialization of our lead drug candidate and of other new
product candidates; expected releases of interim or final data from
our clinical trials; possible collaborations; the timing, scope,
status, objectives of our ongoing and planned trials; the success
of management transitions and strategic initiatives; and other
statements that are not historical. The forward-looking statements
contained in this press release are based on management’s current
expectations and projections which are subject to uncertainty,
risks and changes in circumstances that are difficult to predict
and many of which are outside of our control. These statements
involve known and unknown risks, uncertainties and other factors
which may cause the Company’s actual results, performance or
achievements to be materially different from any historical results
and future results, performance or achievements expressed or
implied by the forward-looking statements. These risks and
uncertainties include but are not limited to: the severity,
duration, and economic impact of the COVID-19 pandemic; our ability
to achieve the intended benefits of our strategic initiatives; that
certain information is of a preliminary nature and may be subject
to change; uncertainties inherent in the cost and outcomes of
research and development, including the cost and availability of
acceptable-quality clinical supply, and the ability to achieve
adequate start and completion dates, as well as uncertainties in
clinical trial design and patient enrollment, dropout or
discontinuation rates; the possibility of unfavorable study
results, including unfavorable new clinical data, additional
analyses of existing data and results that may lead to a
discontinuation of trials; risks associated with early, initial
data, including the risk that the final data from any clinical
trials may differ from prior or preliminary study data or analyses
and may not support further clinical development; and that past
reported data are not necessarily predictive of future patient or
clinical data outcomes; whether and when any applications or other
submissions for SM-88 or other drug candidates may be filed with
regulatory authorities; whether and when regulatory authorities may
approve any applications or submissions; decisions by regulatory
authorities regarding labeling and other matters that could affect
commercial availability of SM-88 or other drug candidates; the
ability of TYME and its collaborators to develop and realize
collaborative synergies; competitive developments; the ability of
TYME to maintain compliance with Nasdaq listing standards; and the
factors described in the section captioned “Risk Factors” of each
of TYME’s Annual Report on Form 10-K for the fiscal year ended
March 31, 2021 filed with the U.S. Securities and Exchange
Commission (“SEC”) on June 10, 2021 and our Quarterly Report on
Form 10-Q for the period ended December 31, 2021 filed with the SEC
on February 11, 2022, as well as subsequent reports we file from
time to time with the U.S. Securities and Exchange Commission
available at www.sec.gov.
The information contained in this press release is as of its
release date and TYME assumes no obligation to update
forward-looking statements contained in this release as a result of
future events or developments.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220325005096/en/
Investor Relations: Lisa M. Wilson, In-Site
Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com
Tyme Technologies (NASDAQ:TYME)
過去 株価チャート
から 10 2024 まで 11 2024
Tyme Technologies (NASDAQ:TYME)
過去 株価チャート
から 11 2023 まで 11 2024
